Abstract
BackgroundStudies conducted thus far have demonstrated that the malaria vaccine (RTS,S) has a promising safety profile. Within the context of planning for future vaccine trials and for the purpose of building on previous research that has been undertaken in sub-Saharan Africa with regard to community perceptions about clinical studies, this research aimed to explore the community perceptions on the secondary health benefits established by the malaria vaccine trials (RTS,S Phase 2 and Phase 3) at the Korogwe site in Tanzania.MethodsAn exploratory qualitative study design was used. Participants were recruited from the Korogwe site. Sampling techniques were purposive and random. A total of five focus group discussions and six in-depth interviews were conducted. Interview guides with open-ended questions were employed to collect data. Male and female parents whose infants participated and those whose infants did not participate in the trials, health workers and community leaders were interviewed. Thematic analysis framework was used to analyse the data.ResultsThe activities of a malaria vaccine project appeared to be well known to the community. Respondents had largely positive views towards the secondary health benefits which have been established by malaria vaccine trials. The project has led to a massive investment in health care infrastructure and an improvement in health care services across the study areas. The project was perceived by the community to have established major secondary health benefits. Misconceptions amongst respondents, especially with regard to blood samples, were also observed in this study.ConclusionDespite some misconceptions with regard to the conduct of malaria vaccine trials, especially on blood sampling, generally this study observed that most participants were positive about the secondary health benefits brought about by the malaria vaccine trials in Korogwe.
Highlights
Studies conducted far have demonstrated that the malaria vaccine (RTS,S) has a promising safety profile
This paper reports the community perceptions on the secondary health benefits established by the malaria vaccine trial (MVT) in the Korogwe site, Tanzania
This study found that the RTS,S MVTs had several secondary health benefits as perceived by community
Summary
Studies conducted far have demonstrated that the malaria vaccine (RTS,S) has a promising safety profile. A malaria vaccine is among the promising new vaccines that are in the final stages of research. The development of this vaccine will save millions of lives, mostly in tropical settings. Malaria persists as a major public health problem, and new tools for controlling the disease are needed to facilitate the current renewed commitment for its control or elimination [3]. Optimal control of malaria disease may be met through a combination of methods such as vector control [4], chemotherapy [4] and/or vaccines [4]. The challenge facing current control efforts, is the development of resistance to anti-malarial drugs and insecticides [4]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
